{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:16:43Z","timestamp":1792088203269,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74277-9","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:11:15Z","timestamp":1735344675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combination of paclitaxel with rosiglitazone induces synergistic cytotoxic effects in ovarian cancer cells"],"prefix":"10.1038","volume":"14","author":[{"given":"Binita","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanaya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foram","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Gelat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Tanavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Vasavada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaid","family":"Johar SR","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"issue":"3","key":"74277_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"Cancer J. Clin."},{"key":"74277_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ebiom.2022.104001","volume":"79","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y., Bi, M., Guo, H. & Li, M. Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. EBioMedicine 79, 1 (2022).","journal-title":"EBioMedicine"},{"key":"74277_CR3","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.ctarc.2022.100629","volume":"33","author":"S Sambasivan","year":"2022","unstructured":"Sambasivan, S. Epithelial ovarian cancer. Cancer Treat. Res. Commun. 33, 100629 (2022).","journal-title":"Cancer Treat. Res. Commun."},{"issue":"6","key":"74277_CR4","first-page":"609","volume":"80","author":"MA Roett","year":"2009","unstructured":"Roett, M. A. & Evans, P. Ovarian cancer: an overview. Am. Family Phys. 80 (6), 609\u2013616 (2009).","journal-title":"Am. Family Phys."},{"key":"74277_CR5","doi-asserted-by":"publisher","first-page":"1102114","DOI":"10.3389\/fgene.2023.1102114","volume":"6","author":"A Mhatre","year":"2023","unstructured":"Mhatre, A. et al. Multi- omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns. Front. Genet. 6, 1102114 (2023).","journal-title":"Front. Genet."},{"key":"74277_CR6","doi-asserted-by":"publisher","first-page":"577869","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang, C. et al. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front. Immunol. 11, 577869 (2020).","journal-title":"Front. Immunol."},{"issue":"7","key":"74277_CR7","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer. 3 (7), 502\u2013516 (2003).","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"74277_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cacc.2008.01.004","volume":"19","author":"C Carr","year":"2008","unstructured":"Carr, C., Ng, J. & Wigmore, T. The side effects of chemotherapeutic agents. Curr. Anaesth. Crit. Care. 19 (2), 70\u201379 (2008).","journal-title":"Curr. Anaesth. Crit. Care"},{"issue":"3","key":"74277_CR9","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.3390\/ijms15034201","volume":"15","author":"LX Feng","year":"2014","unstructured":"Feng, L. X., Li, M., Liu, Y. J., Yang, S. M. & Zhang, N. Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int. J. Mol. Sci. 15 (3), 4201\u20134220 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"74277_CR10","doi-asserted-by":"publisher","first-page":"100110","DOI":"10.1016\/j.crphar.2022.100110","volume":"3","author":"D Duarte","year":"2022","unstructured":"Duarte, D. & Vale, N. Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Curr. Res. Pharmacol. Drug Discov. 3, 100110 (2022).","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"8","key":"74277_CR11","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.3390\/ijms23084280","volume":"23","author":"R Rodrigues","year":"2022","unstructured":"Rodrigues, R., Duarte, D. & Vale, N. Drug repurposing in cancer therapy: influence of patient\u2019s genetic background in breast cancer treatment. Int. J. Mol. Sci. 23 (8), 4280 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"74277_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jphp.13182","volume":"72","author":"J Jean-Pierre","year":"2020","unstructured":"Jean-Pierre, J. Drug repositioning: a brief overview. J. Pharm. Pharmacol. 72, 1 (2020).","journal-title":"J. Pharm. Pharmacol."},{"issue":"12","key":"74277_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nrd2199","volume":"5","author":"JP Overington","year":"2006","unstructured":"Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there?. Nat. Rev. Drug Discov. 5(12), 993\u2013996 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"74277_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0739-7240(01)00117-5","volume":"22","author":"KL Houseknecht","year":"2002","unstructured":"Houseknecht, K. L., Cole, B. M. & Steele, P. J. Peroxisome proliferator-activated receptor gamma (PPAR\u03b3) and its ligands: a review. Domest. Anim. Endocrinol. 22 (1), 1\u201323 (2002).","journal-title":"Domest. Anim. Endocrinol."},{"issue":"1","key":"74277_CR15","doi-asserted-by":"publisher","first-page":"e16179","DOI":"10.1371\/journal.pone.0016179","volume":"6","author":"L Al-Alem","year":"2011","unstructured":"Al-Alem, L., Southard, R. C., Kilgore, M. W. & Curry, T. E. Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPAR\u03b3 independent manner. PLoS One. 6 (1), e16179 (2011).","journal-title":"PLoS One"},{"key":"74277_CR16","doi-asserted-by":"crossref","unstructured":"Lin, C. F. et al. Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. BioMed Res. Int.\u00a0(2014).","DOI":"10.1155\/2014\/787924"},{"issue":"8","key":"74277_CR17","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.4161\/cbt.5.8.2887","volume":"5","author":"W Zhang","year":"2006","unstructured":"Zhang, W. et al. PPAR\u03b3 activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol. Ther. 5 (8), 1008\u20131014 (2006).","journal-title":"Cancer Biol. Ther."},{"key":"74277_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cbi.2018.09.019","volume":"296","author":"YF Dang","year":"2018","unstructured":"Dang, Y. F., Jiang, X. N., Gong, F. L. & Guo, X. L. New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers. Chemico-Biol. Interact. 296, 162\u2013170 (2018).","journal-title":"Chemico-Biol. Interact."},{"key":"74277_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1590\/1414-431x20144212","volume":"48","author":"SY Kim","year":"2015","unstructured":"Kim, S. Y. et al. PPAR\u03b3 induces growth inhibition and apoptosis through upregulation of insulin- like growth factor-binding protein-3 in gastric cancer cells. Braz. J. Med. Biol. Res. 48, 226\u2013233 (2015).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"74277_CR20","doi-asserted-by":"crossref","unstructured":"Mody, M. et al. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-\u03b1, CH11 and CYC202. Endocrine-Relat. Cancer.\u00a0 14(2), 305\u2013315 (2007).","DOI":"10.1677\/ERC-06-0003"},{"issue":"3","key":"74277_CR21","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2353\/ajpath.2009.081078","volume":"175","author":"D Bonofiglio","year":"2009","unstructured":"Bonofiglio, D. et al. Combined low doses of PPAR\u03b3 and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am. J. Pathol. 175 (3), 1270\u20131280 (2009).","journal-title":"Am. J. Pathol."},{"key":"74277_CR22","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. The PPAR\u03b3 agonist rosiglitazone enhances the radio sensitivity of human pancreatic cancer cells. Drug Des. Dev. Ther. 3099\u22123110 (2020).","DOI":"10.2147\/DDDT.S242557"},{"issue":"22","key":"74277_CR23","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u0393 (PPAR\u03b3)\u2217. J. Biol. Chem. 270 (22), 12953\u201312956 (1995).","journal-title":"J. Biol. Chem."},{"key":"74277_CR24","doi-asserted-by":"crossref","unstructured":"Panigraphy, D., Huang, S., Kieran, M. W. & Kaipainen, A. PPAR\u03b3 as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol. Ther.\u00a04(7), 687\u2013693 (2005).","DOI":"10.4161\/cbt.4.7.2014"},{"issue":"2","key":"74277_CR25","first-page":"217","volume":"40","author":"QC Ren","year":"2009","unstructured":"Ren, Q. C., Peng, Z. L. & Tan, X. Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3. Sichuan da xue xue bao. Yi xue ban Journal of Sichuan University. Med. Sci. Ed. 40 (2), 217\u2013222 (2009).","journal-title":"Med. Sci. Ed."},{"key":"74277_CR26","unstructured":"Sara Vignati, V., Albertini, G. M., Carbone, C. V. & Catapano Induction of cell cycle arrest and apoptosis by ligands of peroxisome proliferator- activated receptor gamma in human ovarian cancer cells. Cancer Res.\u00a064(7) (2004)."},{"issue":"7","key":"74277_CR27","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/CAD.0000000000000236","volume":"26","author":"H Zhang","year":"2015","unstructured":"Zhang, H. et al. Suppression of multidrug resistance by rosiglitazone treatment in human ovarian cancer cells through downregulation of FZD1 and MDR1 genes. Anti-Cancer Drugs 26(7), 706\u2013715 (2015).","journal-title":"Anti-Cancer Drugs"},{"key":"74277_CR28","doi-asserted-by":"crossref","unstructured":"Van de Loosdrecht, A. A., Beelen, R. H., Ossenkoppele, G., Broekhoven, M. G. & Langenhuijsen, M. M. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J. Immunol. Methods. 174 (1\u20132), 311\u2013320 (1994).","DOI":"10.1016\/0022-1759(94)90034-5"},{"key":"74277_CR29","doi-asserted-by":"crossref","unstructured":"Shukal, D. et al. Dichloroacetate prevents TGF\u03b2-induced epithelial-mesenchymal transition of retinal pigment epithelial cells. Exp. Eye Res. 197, 108072 (2020).","DOI":"10.1016\/j.exer.2020.108072"},{"key":"74277_CR30","unstructured":"Pahlevan Kakhki, M. TRIzol-based RNA extraction: a reliable method for gene expression studies. J. Sci. Islamic Republic Iran 25(1), 13\u201317 (2014)."},{"issue":"8","key":"74277_CR31","doi-asserted-by":"publisher","first-page":"9959","DOI":"10.3390\/ijms13089959","volume":"13","author":"NA Lokman","year":"2012","unstructured":"Lokman, N. A., Elder, A. S., Ricciardelli, C. & Oehler, M. K. Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int. J. Mol. Sci. 13 (8), 9959\u20139970 (2012).","journal-title":"Int. J. Mol. Sci."},{"key":"74277_CR32","doi-asserted-by":"publisher","first-page":"115576","DOI":"10.1016\/j.taap.2021.115576","volume":"423","author":"P Rathaur","year":"2021","unstructured":"Rathaur, P. et al. Network pharmacology-based evaluation of natural compounds with paclitaxel for the treatment of metastatic breast cancer. Toxicol. Appl. Pharmcol. 423, 115576 (2021).","journal-title":"Toxicol. Appl. Pharmcol."},{"issue":"7","key":"74277_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nbt.1549","volume":"27","author":"J Leh\u00e1r","year":"2009","unstructured":"Leh\u00e1r, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27(7), 659\u2013666 (2009).","journal-title":"Nat. Biotechnol."},{"key":"74277_CR34","doi-asserted-by":"crossref","unstructured":"Miao, R. et al. Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line. Exp. Ther. Med. 2(3), 413-417 (2011).","DOI":"10.3892\/etm.2011.227"},{"issue":"4","key":"74277_CR35","first-page":"833","volume":"18","author":"T Shigeto","year":"2007","unstructured":"Shigeto, T., Yokoyama, Y., Xin, B. & Mizunuma, H. Peroxisome proliferator-activated receptor \u03b1 and \u03b3 ligands inhibit the growth of human ovarian cancer. Oncol. Rep. 18 (4), 833\u2013840 (2007).","journal-title":"Oncol. Rep."},{"key":"74277_CR36","doi-asserted-by":"crossref","unstructured":"Sheu, W. H., Ou, H. C., Chou, F. P., Lin, T. M. & Yang, C. H. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci.\u00a078(13), 1520\u20131528 (2006).","DOI":"10.1016\/j.lfs.2005.07.046"},{"key":"74277_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.biopha.2016.06.047","volume":"83","author":"HY Wang","year":"2016","unstructured":"Wang, H. Y. et al. Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2\/M-phase arrest, independent of PPAR-\u03b3 pathway. Biomed. Pharmacother. 83, 349\u2013361 (2016).","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"74277_CR38","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1535-7163.MCT-08-0308","volume":"7","author":"ME Ramos-Nino","year":"2008","unstructured":"Ramos-Nino, M. E. & Littenberg, B. A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells. Mol. Cancer Ther. 7 (7), 1871\u20131879 (2008).","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"74277_CR39","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/cancers11070916","volume":"11","author":"C Nguyen","year":"2019","unstructured":"Nguyen, C. & Pandey, S. Exploiting mitochondrial vulnerabilities to trigger apoptosis selectively in cancer cells. Cancers. 11 (7), 916 (2019).","journal-title":"Cancers"},{"key":"74277_CR40","first-page":"1243613","volume":"25","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. The mechanisms of action of mitochondrial targeting agents in cancer: inhibiting oxidative phosphorylation and inducing apoptosis. Front. Pharmacol. 2023 Oct. 25, 1243613 (2023).","journal-title":"Front. Pharmacol. 2023 Oct."},{"issue":"6","key":"74277_CR41","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1745-7254.2007.00571.x","volume":"28","author":"LQ Cao","year":"2007","unstructured":"Cao, L. Q. et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells 1. Acta Pharmacol. Sin. 28(6), 879\u2013887 (2007).","journal-title":"Acta Pharmacol. Sin."},{"key":"74277_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00280-019-04025-8","volume":"85","author":"Z Wang","year":"2020","unstructured":"Wang, Z., Gao, J., Ohno, Y., Liu, H. & Xu, C. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib. Cancer Chemother. Pharmacol. 85, 273\u2013284 (2020).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"74277_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1309\/LMOTQ5MUG76FMYMK","volume":"40","author":"JJ Liu","year":"2009","unstructured":"Liu, J. J., Zhang, Y., Xiao, R. Z. & Lin, D. J. Peroxisome proliferator-activated receptor \u03b3 (PPAR-\u03b3) agonist rosiglitazone (RGZ) inhibits HL-60 cell growth by induction of apoptosis. Lab. Med. 40 (5), 297\u2013302 (2009).","journal-title":"Lab. Med."},{"issue":"2","key":"74277_CR44","first-page":"979","volume":"40","author":"G Wang","year":"2018","unstructured":"Wang, G., Zhou, H., Gu, Z., Gao, Q. & Shen, G. Oct4 promotes cancer cell proliferation and migration and leads to poor prognosis associated with the survivin\/STAT3 pathway in hepatocellular carcinoma. Oncol. Rep. 40 (2), 979\u2013987 (2018).","journal-title":"Oncol. Rep."},{"issue":"4","key":"74277_CR45","doi-asserted-by":"publisher","first-page":"165432","DOI":"10.1016\/j.bbadis.2019.03.005","volume":"1866","author":"IS Mohiuddin","year":"2020","unstructured":"Mohiuddin, I. S., Wei, S. J. & Kang, M. H. Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 1866(4), 165432 (2020).","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"issue":"8","key":"74277_CR46","doi-asserted-by":"publisher","first-page":"e760","DOI":"10.1038\/cddis.2013.272","volume":"4","author":"YD Wang","year":"2013","unstructured":"Wang, Y. D. et al. OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b\/BAK1 pathway. Cell Death Dis. 4 (8), e760 (2013).","journal-title":"Cell Death Dis."},{"issue":"8","key":"74277_CR47","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1002\/stem.2007","volume":"33","author":"CR Jeter","year":"2015","unstructured":"Jeter, C. R., Yang, T., Wang, J., Chao, H. P. & Tang, D. G. Concise review: NANOG in cancer stem cells and tumor development: an update and outstanding questions. Stem Cells. 33 (8), 2381\u20132390 (2015).","journal-title":"Stem Cells"},{"issue":"6","key":"74277_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2021.8053","volume":"45","author":"L Gao","year":"2021","unstructured":"Gao, L. et al. EHF enhances malignancy by modulating AKT and MAPK\/ERK signaling in non-small cell lung cancer cells. Oncol. Rep. 45 (6), 1\u20132 (2021).","journal-title":"Oncol. Rep."},{"issue":"6","key":"74277_CR49","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/mc.22349","volume":"55","author":"Z Cheng","year":"2016","unstructured":"Cheng, Z. et al. Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells. Mol. Carcinog. \u00ee55 (6), 1048\u20131059 (2016).","journal-title":"Mol. Carcinog."},{"key":"74277_CR50","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10456-008-9118-0","volume":"11","author":"A Aljada","year":"2008","unstructured":"Aljada, A., O\u2019Connor, L., Fu, Y. Y. & Mousa, S. A. PPAR\u03b3 ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis. Angiogenesis. 11, 361\u2013367 (2008).","journal-title":"Angiogenesis"},{"key":"74277_CR51","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10456-013-9334-0","volume":"16","author":"G Bocci","year":"2013","unstructured":"Bocci, G., Di Paolo, A. & Danesi, R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis. 16, 481\u2013492 (2013).","journal-title":"Angiogenesis"},{"issue":"24","key":"74277_CR52","doi-asserted-by":"publisher","first-page":"6246","DOI":"10.3390\/cancers14246246","volume":"14","author":"KL Alatise","year":"2022","unstructured":"Alatise, K. L., Gardner, S. & Alexander-Bryant, A. Mechanisms of drug resistance in ovarian cancer and associated gene targets. Cancers. 14 (24), 6246 (2022).","journal-title":"Cancers"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74277-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74277-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T01:05:52Z","timestamp":1735347952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74277-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74277"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74277-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"13 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30672"}}